|
Name |
24-Hydroxylergosta-4,6,8(14),22-tetraen-3-one
|
Molecular Formula | C28H40O2 | |
IUPAC Name* |
(9R,10R,13R,17R)-17-[(2R)-5-hydroxy-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-1,2,9,11,12,15,16,17-octahydrocyclopenta[a]phenanthren-3-one
|
|
SMILES |
C[C@H](C=CC(C)(C(C)C)O)[C@H]1CCC2=C3C=CC4=CC(=O)CC[C@@]4([C@H]3CC[C@]12C)C
|
|
InChI |
InChI=1S/C28H40O2/c1-18(2)28(6,30)16-11-19(3)23-9-10-24-22-8-7-20-17-21(29)12-14-26(20,4)25(22)13-15-27(23,24)5/h7-8,11,16-19,23,25,30H,9-10,12-15H2,1-6H3/t19-,23-,25+,26+,27-,28?/m1/s1
|
|
InChIKey |
VCRVBLLMTMHOEY-BZABDROBSA-N
|
|
Synonyms |
24-hydroxylergosta-4,6,8(14),22-tetraen-3-one
|
|
CAS | NA | |
PubChem CID | 139590508 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 408.6 | ALogp: | 5.6 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 37.3 | Aromatic Rings: | 4 |
Heavy Atoms: | 30 | QED Weighted: | 0.537 |
Caco-2 Permeability: | -4.989 | MDCK Permeability: | 0.00001670 |
Pgp-inhibitor: | 1 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.915 |
30% Bioavailability (F30%): | 0.302 |
Blood-Brain-Barrier Penetration (BBB): | 0.002 | Plasma Protein Binding (PPB): | 96.06% |
Volume Distribution (VD): | 1.529 | Fu: | 2.26% |
CYP1A2-inhibitor: | 0.052 | CYP1A2-substrate: | 0.568 |
CYP2C19-inhibitor: | 0.442 | CYP2C19-substrate: | 0.936 |
CYP2C9-inhibitor: | 0.522 | CYP2C9-substrate: | 0.164 |
CYP2D6-inhibitor: | 0.455 | CYP2D6-substrate: | 0.176 |
CYP3A4-inhibitor: | 0.933 | CYP3A4-substrate: | 0.906 |
Clearance (CL): | 1.254 | Half-life (T1/2): | 0.477 |
hERG Blockers: | 0.597 | Human Hepatotoxicity (H-HT): | 0.176 |
Drug-inuced Liver Injury (DILI): | 0.103 | AMES Toxicity: | 0.014 |
Rat Oral Acute Toxicity: | 0.097 | Maximum Recommended Daily Dose: | 0.901 |
Skin Sensitization: | 0.955 | Carcinogencity: | 0.098 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.037 |
Respiratory Toxicity: | 0.953 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003739 | 0.822 | D0G8BV | 0.339 | ||||
ENC004022 | 0.780 | D0F1UL | 0.339 | ||||
ENC001861 | 0.780 | D04GJN | 0.304 | ||||
ENC004737 | 0.780 | D0Z1XD | 0.300 | ||||
ENC003667 | 0.761 | D06XMU | 0.294 | ||||
ENC004998 | 0.758 | D04ATM | 0.291 | ||||
ENC003368 | 0.755 | D06JPB | 0.286 | ||||
ENC004834 | 0.745 | D0I2SD | 0.282 | ||||
ENC005009 | 0.640 | D0W5LS | 0.281 | ||||
ENC004736 | 0.604 | D0N1TP | 0.281 |